Pharmaceuticals

IX Biopharma

IX Biopharma released FY2026 9 Months Earnings on May 8, 2026 (SGT) with actual revenue of SGD 4.764 M and EPS of SGD -0.0032

IX Biopharma released FY2026 Q3 earnings on May 8, 2026 (SGT), actual revenue SGD 1.589 M, actual EPS SGD -0.0009

IX Biopharmaceuticals Obtains SGX-ST Listing Approval, Plans to Raise Funds Through Rights Issue

IX Biopharma released FY2026 Semi-Annual earnings on February 8, 2026 (SGT), with actual revenue of SGD 3.175 M and EPS of SGD -0.0023

IX Biopharma released FY2026 Q2 earnings on February 8, 2026 (SGT) with actual revenue of SGD 1.588 M and EPS of SGD -0.0011

IX Biopharma released FY2026 Q1 earnings on February 8, 2026 (SGT), actual revenue SGD 1.588 M, actual EPS SGD -0.0011

IX Biopharma released FY2025 Annual Earnings on August 29, 2025 (SGT) with actual revenue of SGD 7.767 M and EPS of SGD -0.0116

IX Biopharma released FY2025 9 Months Earnings on August 29 SGT, with actual revenue of SGD 5.74 M and EPS of SGD -0.0094

IX Biopharma released FY2025 Q3 earnings on August 29, 2025 (SGT) with actual revenue of SGD 2.027 M and EPS of SGD -0.0022

IX Biopharma released FY2025 Q4 earnings on August 29 (SGT), actual revenue SGD 2.027 M, actual EPS SGD -0.0022

IX Biopharma released FY2025 Semi-Annual Earnings on February 7, 2025 (SGT) with actual revenue of 3.713 M SGD and EPS of -0.0072 SGD

IX Biopharma released FY2025 Q2 earnings on February 7, 2025 (SGT), with actual revenue of SGD 1.857 M and EPS of SGD -0.0035

IX Biopharma released FY2025 Q1 earnings on February 7, 2025 (SGT) with actual revenue of 1.857 M SGD and EPS of -0.0036 SGD

IX Biopharma released FY2022 Q3 earnings on August 22 (SGT) with actual revenue of 602.5K SGD and EPS of -0.0055

IX Biopharma released FY2021 Q3 earnings on August 23, 2021 (SGT) with revenue of 457.5K SGD and EPS of -0.0038

SingtelMBeCW260730

Geely MB ePW261005

Autagco

Asian Micro

HSI 28000MBePW260629

Teho

Acesian Partners

NKY 55000MBePW260911

NKY 52000MBePW260612

Landmark REIT

iX Biopharma Ltd. has received conditional approval from the Singapore Exchange for the issuance of 1,349,434 new ordinary shares under proposed placements to Anson Properties Pte. Ltd. and certain directors. This approval is contingent upon shareholder endorsement at an extraordinary general meeting on May 8, 2026. The placements aim to strengthen the company's capital base, with further announcements expected as developments occur. The current analyst rating for iX Biopharma is a Buy, with a price target of S$1.00.

Tip Ranks

$ IX BiopharmaR1

$ IX BiopharmaR

iX Biopharma Wins Conditional SGX Nod for New Share Placement

Singapore-listed IX Biopharma is focusing on non-opioid pain relief, believing it has an advantage in this emerging market. The company's main product, Wafermine, is a sublingual ketamine wafer that provides quick pain relief without the addiction risks associated with opioids. Since its 2015 listing on the Singapore Exchange, IX Biopharma has been advancing Wafermine through necessary clinical trials for regulatory approval.

Businesstimes News

Singapore-listed IX Biopharma bets big on non-opioid pain relief

CY6U

SGX-listed stocks have seen an average daily turnover of S$1.7 billion in early 2026, with institutions net buying across various sectors. Valuemax Group broadened its institutional base through a 34.8 million share block trade, while CapitaLand India Trust raised S$150 million for developments. iX Biopharma issued 75.8 million shares to strengthen liquidity for a US Government contract. Valuemax reported record profits and increased dividends, while CLINT's placement is expected to enhance DPU and reduce gearing, supporting growth into FY26.

CapLand India T

ValueMax

Liquidity & Capital: Institutional Participation Continues to Broaden across SGX

iX Biopharma Ltd. has received approval from the Singapore Exchange for the listing of up to 75.8 million new shares in a proposed placement expected to raise at least $6 million. The placement agreement was made with OCBC, and the approval is contingent on meeting the exchange's listing requirements. The company previously announced the placement results on February 13, and the approval does not indicate the merits of the placement or the company’s shares.

Singapore Business Review

iX Biopharma gets SGX nod to list 75.8 million shares in $6m placement

Singapore biopharmaceutical company IX Biopharma has received a research and development contract worth $40.95 million from the U.S. Department of Defense to develop sublingual ketamine tablets for the treatment of moderate to severe acute pain. To fulfill the contract, the company plans to issue new shares at a price of 19.8 cents per share to raise 6 million yuan, representing a discount of 7.1%. The contract will be executed on a cost-reimbursement basis, and IX Biopharma's stock has resumed trading, with the current stock price at 0.20 yuan, down 4.76%

Zaobao

Singapore-listed IX Biopharma receives a USD 40.95 million contract from the U.S. government to develop painkillers | Lianhe Zaobao

iX Biopharma Ltd. reported a narrowed net loss of $2.1 million for H1 FY 2026, down from $6.3 million in H1 FY 2025, despite a 14% revenue decline to $3.2 million. The loss per share improved to $0.0023 from $0.0072. The company's balance sheet strengthened, with total equity rising to $4.1 million from $365,000 as of June 30.

iX Biopharma narrows losses in H1 FY 2026 despite 14% fall in revenue